MIBG Scan vs DOTATATE PET: — Which Scan for Which Disease?

For most adult neuroendocrine tumours, DOTATATE PET gives clearer images and is now preferred by NCCN and ESMO. For childhood neuroblastoma, MIBG remains the standard — not because it is superior overall, but because it matches that tumour's biology and also guides treatment decisions. Whether one is more appropriate depends entirely on what disease is being imaged and what the scan needs to answer.

MIBG scan is the standard of care for neuroblastoma staging and restaging in children, according to COG and NCCN guidelines. It is done at diagnosis, after chemotherapy cycles, and before surgery. DOTATATE PET is being studied in this setting and shows promise in early research, but it has not replaced MIBG in standard protocols. Your child's treating team will follow established COG criteria.

Yes, and in some situations that is exactly what happens. An MIBG scan may be needed to confirm MIBG-therapy eligibility, while a DOTATATE PET maps receptor expression across all lesions. Some protocols also use both when results from one scan are inconclusive. Your oncologist decides which combination gives the most useful information for your specific diagnosis and planned treatment.

MIBG is a two-visit scan. The injection is given on the first visit and images are taken the following day, so the process spans 24–48 hours. DOTATATE PET is a single-visit scan; images are acquired roughly 60–90 minutes after the injection, and the scan itself takes around 20–30 minutes. Total time in the centre is typically two to three hours.

The indicative fee is ₹23,999 (2025 pricing) at CION's partner PET imaging centres. This is an approximate figure and may vary by centre or depending on whether your health insurance covers part of the cost. Confirm the current fee when you book. CION coordinates the appointment with its partner imaging centre — the scan is not performed at the CION clinic itself.

Not all neuroendocrine tumours take up either tracer reliably. Poorly differentiated or high-grade neuroendocrine carcinomas often express fewer somatostatin receptors and less noradrenaline-transporter activity, which means both scans can appear negative even when active disease is present. In that situation, FDG PET/CT — which images metabolic activity rather than receptor expression — is usually more informative. Your oncologist will decide which scan suits your tumour's grade and behaviour.